Myozyme (Alglucosidase Alfa)

Alglucosidase alfa, the active ingredient in Myozyme, is a recombinant human enzyme presented as a 5 mg/mL solution for injection for intravenous use. It treats Pompe disease, including infantile‑onset and late‑onset forms, by replacing deficient acid alpha‑glucosidase activity.

GNH USA supplies Myozyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myozyme is used in enzyme replacement therapy for glycogen storage disease type II (Pompe disease). - Infantile‑onset Pompe disease: improves survival and motor development by providing functional acid alpha‑glucosidase. - Late‑onset Pompe disease: slows progression of respiratory and skeletal muscle weakness through glycogen clearance. - Acid alpha‑glucosidase deficiency (Pompe disease): reduces lysosomal glycogen accumulation, helping maintain organ function.

Myozyme may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions such as fever, chills, or flushing. - Headache. - Nausea or vomiting. - Rash or pruritus.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions. - Respiratory distress or bronchospasm. - Cardiac arrhythmias. - Elevated liver enzymes or thrombocytopenia.

When using Myozyme, several precautions should be observed to ensure patient safety. - Cardiac monitoring: assess baseline and ongoing cardiac function due to potential arrhythmias. - Respiratory assessment: evaluate pulmonary status before and during infusion. - Antibody testing: check for anti‑drug antibodies that may affect efficacy. - Dose adjustment: consider renal or hepatic impairment when determining infusion rate. - Hypersensitivity: discontinue infusion if severe allergic reaction occurs. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myozyme can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection. - Other enzyme replacement therapies: may compete for cellular uptake pathways. - High‑dose immunosuppressants: can diminish immune response to the enzyme.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of infusion reactions. - Beta‑blockers: can blunt heart rate changes used to monitor infusion safety. - ACE inhibitors or ARBs: monitor blood pressure during infusion.